TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02373150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01801709

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: intracerebral administration of AAVrh.10cuARSA
Study: NCT03063736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entolimod
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Td Vaccine
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Td Vaccine
Description: The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
Study: NCT04453761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurobion
Description: Intravenous Thiamine 2 mg/kg in Neurobion injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous NaCl0.9%
Study: NCT01285869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Description: The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
Study: NCT02303600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
Study: NCT03973853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality driving stimulation program
Description: This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU
Description: This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
Study: NCT03221166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
Study: NCT02738359

Intervention type: PROCEDURE
Intervention: optical colonoscopy
Description: optical colonoscopy

Intervention type: PROCEDURE
Intervention: optical colonoscopy
Description: optical colonoscopy
Study: NCT03221166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab is a chimeric monoclonal antibody against TNF alpha
Study: NCT01644084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyethyl starch 130/0.4
Description: Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
Study: NCT03434444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin in solution, ranging from 10 -12M to 10 -5M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin in solution, ranging from 10 -12M to 10 -5M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin in solution, ranging from 10 -12M to 10 -5M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin in solution, ranging from 10 -12M to 10 -5M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin in solution, ranging from 10 -12M to 10 -5M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol in solution, 10-6M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol in solution, 10-6M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol in solution, 10-6M

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol in solution, 10-6M
Study: NCT04168970

Intervention type: PROCEDURE
Intervention: PSGB
Description: Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
Study: NCT02334280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In SHAPE
Description: In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
Study: NCT03261687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water based exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: land based exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advice
Description: general advice given to all subjects

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advice
Description: general advice given to all subjects
Study: NCT02738359

Intervention type: PROCEDURE
Intervention: optical colonoscopy
Description: optical colonoscopy

Intervention type: PROCEDURE
Intervention: colon capsule endoscopy
Description: colon capsule endoscopy
Study: NCT04243746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Subjects practise TRF (2-3 meals) as an adjunct to the QQH healthy plate diet. Subjects of the intervention group can eat during the pre-determined 8-12 hours eating window, but they are only allowed to drink water and calorie-free drinks for the remaining 12-16 hours. Subjects are allowed to decide the time of their first and the last meal of the day as long as they eat within the 8-12 hour window period. However, skipping breakfast and having late dinner are discouraged.
Study: NCT02738359

Intervention type: DIAGNOSTIC_TEST
Intervention: fecal immunological test (FIT)
Description: fecal immunological test (FIT)
Study: NCT01598805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic alerts
Description: An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
Study: NCT04243746

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects practice the QQH healthy plate diet as per guidelines set by the Health Ministry the guidelines.QQH refers to a normal food plate (23cm in diameter), divided into a quarter of rice (carbohydrates), a quarter of meat (protein) and a half plate of vegetables and fruits. Additionally, no calories specification is required and snacks are discouraged.
Study: NCT02879786

Intervention type: OTHER
Group type: OTHER
Intervention: Posturographic tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posturographic tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posturographic tests

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire of motion sickness susceptibility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of motion sickness susceptibility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of motion sickness susceptibility
Study: NCT01162863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lubiprostone
Description: lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
Study: NCT02899065

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-Led Education
Description: Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
Study: NCT01162863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taken orally for 28 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartpill wireless motility capsule
Description: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartpill wireless motility capsule
Description: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smartpill wireless motility capsule
Description: Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
Study: NCT00631267

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Manual Manipulation
Description: The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Finger Trap Traction
Description: Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
Study: NCT02849444

Intervention type: OTHER
Intervention: Anti-myeloma treatment at physician discretion
Description: non Interventional Study

Intervention type: OTHER
Intervention: Anti-myeloma treatment at physician discretion
Description: non Interventional Study
Study: NCT05142007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction
Description: A number of steps are taken to make the treatment arms identical in all other respects. The participants are unaware that there are two treatment arms to homogenize expectations. Each session is a manualized hypnosis script which is dictated by the hypnotist, including the hypnosis test. The only degrees of freedom for the hypnotist is in intonation and speed. Identical induction and termination is used in both arms and the scripts are of comparable durations.
Study: NCT04230122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478006 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3478006 - SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC
Study: NCT04663685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Participants received two 1-on-1 exercise sessions per week to start. Each session lasted 30 minutes. As progress was made, participants were encouraged to exercise independently outside the structured sessions while continuing to receive a 1-on-1 session each week. The individualized exercises were aligned with functional movements to promote personal relevance: balance, pull, squat, push, hinge, lift \& carry and calf raise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Participants received a nutrition education booklet and had access to five online videos that correspond to key topics in the booklet (reading nutrition labels, types of protein, foods containing protein, incorporating protein into meals, spreading protein in meals throughout the day). Participants attended three 60-minute nutrition Q\&A sessions led by a dietitian, where the group reviewed content from the booklet and videos, and discussed personalized strategies to increase protein intake.
Study: NCT03764280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Daily Injections: Slow acting insulin and Rapid acting insulin
Description: Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
Study: NCT04195061

Intervention type: PROCEDURE
Intervention: Cardiopulmonary exercise test (CPET)
Description: CPET studies will be performed in the Cardiovascular Performance Program exercise lab at MGH. Subjects will undergo CPET on an upright cycle ergometer with continual measurement of metabolic gas exchange via a commercially available metabolic cart as well as heart rate and blood pressure. Exercise will proceed according to a maximal effort clinical protocol. Subjects will then undergo a standardized 30-min work load on the upright cycle ergometer based on the results of the maximal effort clinical protocol.
Study: NCT01921803

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation
Study: NCT01701804

Intervention type: DRUG
Intervention: Chuna herbal medicine
Description: 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks

Intervention type: PROCEDURE
Intervention: Chuna manual therapy
Description: A type of Korean spinal manual therapy administered 5\~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15\~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10\~20 acupoints once a week for 16 weeks.

Intervention type: PROCEDURE
Intervention: Bee-venom pharmacoacupuncture
Description: Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
Study: NCT01124318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactofiltrum
Description: Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 tablets 3 times a day before meals during 21 days
Study: NCT05796700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microwave Ablation
Description: Microwave Ablation: A minimally invasive technique for HCC, MWA has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor.~Laparoscopic Hepatectomy: The technique has been widely promoted worldwide with technical progress. In patients with cirrhosis, LLR has the potential advantage of reducing the risk of postoperative liver decompensation
Study: NCT02589470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMETE
Description: Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
Study: NCT01976481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sunbed exposure
Description: exposure to sunbed ultraviolet radiation
Study: NCT02550743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study: NCT01077323

Intervention type: DRUG
Intervention: exenatide
Description: subcutaneous injection, dosing according to normal clinical practice

Intervention type: DRUG
Intervention: Other antidiabetic therapies
Description: Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice

Intervention type: OTHER
Intervention: No diabetes therapy
Description: Subjects not diagnosed with diabetes
Study: NCT05628701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileorectal anastomosis (IRA)
Description: After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileorectal anastomosis (IRA)
Description: After subtotal colectomy for ulcerative colitis the patients can either keep their end ileostomy or be reconstructed with an anastomosis (connection) between the ileum and the rectal remnant (Ileorectal anastomosis(IRA))

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileal pouch anal anastomosis (IPAA)
Description: The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileal pouch anal anastomosis (IPAA)
Description: The rectum is removed and a pouch constructed with the distal part opf the ileum which in subsequently anastomosed (connected) to the anus(Ileal pouch anal anastomosis (IPAA)).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ileostomy
Description: no reconstruction is performed and the patient is left with his/her ileostomy